California Plans To Create Own Generics Label
Aiming To Regain Power From ‘Greedy’ Industry
California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.
You may also be interested in...
California is set to begin producing its own biosimilar insulin products, having been designated $100m by state governor Gavin Newsom to complete the project.
With the legislature’s green light on California’s Generic Drug Pricing Bill, the state aims to manufacture generics while addressing shortages in the prescription drug market, expanding access to life-saving generic prescription drugs and improving patient health outcomes and overall public health.
Responding to a California district court’s denial of an injunction to prevent the enactment of the US state’s legislation banning ‘pay-for-delay’ settlement deals, the AAM has confirmed plans to immediately appeal the decision.